FDA milestones put Larimar Therapeutics (LRMR) and nomlabofusp in sharper focus

Larimar Therapeutics (LRMR) is back on investors’ radar after the FDA granted Breakthrough Therapy Designation to its Friedreich's ataxia candidate nomlabofusp and signaled openness to a surrogate endpoint supporting a potential accelerated approval filing.

The FDA update has arrived alongside a sharp pickup in momentum, with a 1 day share price return of 31.32% and a 7 day share price return of 21.78% lifting Larimar to US$3.69. This comes even as the 5 year total shareholder return of 79.03% decline shows how sentiment around the story has shifted over time.

If rare disease progress is on your mind after Larimar's FDA news, it could be worth scanning other healthcare names through our screener of 28 healthcare AI stocks as potential next ideas.

With Larimar still trading at US$3.69 versus an analyst price target of US$16.30, recent FDA momentum raises a key question for investors: is there unrealized upside here, or is the market already pricing in future growth?

Price to book of 2.3x, is it justified?

Larimar is trading on a P/B of 2.3x, which sits below both its direct peer group average of 3.1x and the wider US biotech average of 2.6x.

P/B compares the market value of the company to the book value of its net assets. It is often used for early stage or loss making biotechs where earnings do not yet provide a meaningful signal. For Larimar, ongoing losses, a reported net income loss of $132.0m and a negative return on equity of 94.94% mean asset based markers like P/B can be a useful cross check on how much investors are paying for the current balance sheet and pipeline.

The fact that Larimar's 2.3x P/B sits below both its peer average of 3.1x and the broader US biotech sector at 2.6x suggests the market is currently pricing the company at a discount to many other development stage names with similar asset backing. That discount could reflect its history of losses growing at 20.3% per year over the past 5 years and forecasts that the company will remain unprofitable for at least the next 3 years, even while revenue is projected to grow about 59% per year and faster than both the US market and the biotech industry.

Result: Price to book of 2.3x (UNDERVALUED)

However, you still need to weigh clinical trial risk around nomlabofusp and ongoing net losses of $132.0m, which could pressure funding needs and sentiment.

Next Steps

Given the mix of excitement around nomlabofusp and the clear risks on the table, it makes sense to check the numbers yourself and move quickly to a view you trust, starting with 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If Larimar has sharpened your focus on risk, reward and timing, do not stop here. The next opportunity you care about could already be on someone else's list.

• Spot potential mispricings early by checking out 51 high quality undervalued stocks that pair strong fundamentals with prices that may not fully reflect them.
• Prioritise resilience by reviewing 78 resilient stocks with low risk scores, where companies rate well on financial strength and business stability.
• Hunt for future standouts before they hit the headlines using our screener containing 23 high quality undiscovered gems built around quality metrics, not hype.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.